Drug Trial Radar · NCT05645107
A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
386
Planned (sponsor's estimate)
Start
Dec 26, 2022
Primary completion
Aug 2029
Study completion Aug 2029
Sponsor
- Lead sponsor
- Grifols Therapeutics LLCIndustry
- Sponsor type
- Industry
- First posted
- Dec 9, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of the study is to evaluate whether biweekly administered XEMBIFY® plus Standard Medical Treatment (SMT) over a one-year period will reduce the rate of major bacterial infections per participant per year in B-cell CLL, MM, and NHL participants with hypogammaglobulinemia (HGG) in comparison to the Placebo plus SMT group.
Conditions
- Hypogammaglobulinemia
- Bacterial Infections
- B-cell Chronic Lymphocytic Leukemia
- Multiple Myleoma
- Non-Hodgkin Lymphoma
Interventions
XembifyDrug
SC infusion pump
PlaceboDrug
SC infusion pump
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annual Rate of Major Bacterial Infections per YearTime frame: Up to Week 51
Locations
62 sites in 8 countries. Site status is shown where the registry gives one.
GC2202 Study Site 118
Bullhead City, Arizona · Recruiting
GC2202 Study Site 115
Huntington Park, California · Recruiting
GC2202 Study Site 103
St. Petersburg, Florida · Recruiting
GC2202 Study Site 111
Bethesda, Maryland · Recruiting
GC2202 Study Site 109
Greenville, North Carolina · Recruiting
GC2202 Decentralized Study Site 114
Morrisville, North Carolina · Recruiting
GC2202 Study Site 117
Wilson, North Carolina · Recruiting
GC2202 Study Site 105
Canton, Ohio · Recruiting
GC2202 Study Site 110
Rockville, South Carolina · Withdrawn
GC2202 Study Site 702
Banja Luka, Bosnia and Herzegovina · Recruiting
GC2202 Study Site 703
Mostar, Bosnia and Herzegovina · Recruiting
GC2202 Study Site 701
Sarajevo, Bosnia and Herzegovina · Not yet recruiting
GC2202 Study Site 202
Burgas, Bulgaria · Recruiting
GC2202 Study Site 203
Plovdiv, Bulgaria · Recruiting
GC2202 Study Site 210
Plovdiv, Bulgaria · Recruiting
GC2202 Study Site 205
Rousse, Bulgaria · Recruiting
GC2202 Study Site 209
Sofia, Bulgaria · Recruiting
GC2202 Study Site 201
Sofia, Bulgaria · Recruiting
GC2202 Study Site 206
Sofia, Bulgaria · Recruiting
GC2202 Study Site 207
Sofia, Bulgaria · Recruiting
GC2202 Study Site 211
Sofia, Bulgaria · Recruiting
GC2202 Study Site 212
Sofia, Bulgaria · Recruiting
GC2202 Study Site 213
Sofia, Bulgaria · Recruiting
GC2202 Study Site 204
Sofia, Bulgaria · Recruiting
GC2202 Study Site 208
Sofia, Bulgaria · Recruiting
GC2202 Study Site 214
Stara Zagora, Bulgaria · Recruiting
GC2202 Study Site 801
Rijeka, Croatia · Recruiting
GC2202 Study Site 802
Zagreb, Croatia · Recruiting
GC2202 Study Site 301
Budapest, Hungary · Recruiting
GC2202 Study Site 308
Budapest, Hungary · Recruiting
GC2202 Study Site 306
Debrecen, Hungary · Recruiting
GC2202 Study Site 304
Eger, Hungary · Recruiting
GC2202 Study Site 302
Győr, Hungary · Recruiting
GC2202 Study Site 307
Szeged, Hungary · Recruiting
GC2202 Study Site 303
Szekszárd, Hungary · Recruiting
GC2202 Study Site 305
Székesfehérvár, Fejér, Hungary · Withdrawn
GC2202 Study Site 408
Bydgoszcz, Poland · Recruiting
GC2202 Study Site 410
Krakow, Poland · Recruiting
GC2202 Study Site 409
Olsztyn, Poland · Recruiting
GC2202 Study Site 407
Torun, Poland · Withdrawn
Showing 40 of 62 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.